Charles River to divest CDMO/Cell Solutions and European Discovery assets; updates 2026 guidance

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Definitive agreement to sell CDMO and Cell Solutions to GI Partners for future performance-based payments; $143M 2025 revenue.
Agreement to sell certain European Discovery Services assets to IQVIA for ~$145M cash plus up to $10M contingent; $144M 2025 revenue.
Updated 2026 guidance: reported revenue growth (5.0)% to (3.5)%; non-GAAP EPS $10.80-$11.30.
Divestitures expected to reduce 2026 reported revenue by >$200M, but add at least 100 bps non-GAAP operating margin and ~$0.10 EPS.
Both transactions expected to close in Q2 2026, subject to customary closing conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.